» Articles » PMID: 7542622

Expression and Function of Beta 1 and Alpha V Beta 3 Integrins in Ovarian Cancer

Overview
Journal Gynecol Oncol
Date 1995 Aug 1
PMID 7542622
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Ovarian cancer cells disseminate by implanting onto the peritoneal mesothelial cell surface of the abdominal cavity. A common feature of these peritoneal implants is the presence of tumor cell invasion into the submesothelial extracellular matrix (ECM). In view of the important role of integrins in ECM recognition and cell migration, we were interested in defining the pattern of integrin expression and function in ovarian cancer cell lines and primary tissue samples. The beta 1 integrin chain was expressed by CAOV-3, SKOV-3, OVCAR-3, and SW626 ovarian cancer cell lines, associated with expression of alpha 1, -2, -3, -5, and -6 chains. The alpha 4 chain was also expressed by two of the four lines. In addition to beta 1 integrins, the alpha v beta 3 integrin was also expressed, although there was no expression of beta 2, -4, and -7 chains. Immunoprecipitation of surface-labeled CAOV-3 cells with an anti-beta 1 antibody revealed a band at approximately 110-130 kDa consistent with the known molecular mass of the beta 1 chain, as well as several associated bands consistent with noncovalently linked integrin alpha chains. A similar pattern of beta 1 and alpha v beta 3 integrin expression was observed for primary ovarian cancer tissue samples. Ovarian cancer cell lines exhibited significant binding to collagen type I and laminin which was primarily mediated by beta 1 integrins. In contrast, ovarian cancer cell binding to fibronectin was mediated by both alpha 5 beta 1 and alpha v beta 3 integrins. Even though mesothelial cells were observed to express fibronectin mRNA and protein, binding of ovarian cancer cells to peritoneal mesothelium was not blocked by neutralizing antibodies to beta 1 or alpha v beta 3 integrins. These data suggest that functional integrins are commonly expressed by ovarian cancer cells, although they do not appear to mediate ovarian cancer cell implantation onto peritoneal mesothelium. The role that integrins play in the invasion of ovarian cancer cells into the submesothelial ECM deserves further investigation.

Citing Articles

RGD-Conjugated Resveratrol HSA Nanoparticles as a Novel Delivery System in Ovarian Cancer Therapy.

Long Q, Zhu W, Guo L, Pu L Drug Des Devel Ther. 2021; 14:5747-5756.

PMID: 33408463 PMC: 7779302. DOI: 10.2147/DDDT.S248950.


Tumor-mesoporous silica nanoparticle interactions following intraperitoneal delivery for targeting peritoneal metastasis.

Hargrove D, Liang B, Kashfi-Sadabad R, Joshi G, Gonzalez-Fajardo L, Glass S J Control Release. 2020; 328:846-858.

PMID: 33166606 PMC: 7749032. DOI: 10.1016/j.jconrel.2020.11.003.


The identification of nuclear αvβ3 integrin in ovarian cancer: non-paradigmal localization with cancer promoting actions.

Seraya-Bareket C, Weisz A, Shinderman-Maman E, Teper-Roth S, Stamler D, Arbib N Oncogenesis. 2020; 9(7):69.

PMID: 32728020 PMC: 7391722. DOI: 10.1038/s41389-020-00254-2.


Soluble matrix protein is a potent modulator of mesenchymal stem cell performance.

Yeo G, Weiss A Proc Natl Acad Sci U S A. 2019; 116(6):2042-2051.

PMID: 30659152 PMC: 6369744. DOI: 10.1073/pnas.1812951116.


Role of tumor microenvironment in ovarian cancer pathobiology.

Ghoneum A, Afify H, Salih Z, Kelly M, Said N Oncotarget. 2018; 9(32):22832-22849.

PMID: 29854318 PMC: 5978268. DOI: 10.18632/oncotarget.25126.